1
|
Mattei I, Alexandrov A, Alunni Solestizi L, Ambrosi G, Argiro S, Bartosik N, Battistoni G, Belcari N, Biondi S, Bisogni MG, Bruni G, Camarlinghi N, Carra P, Catanzani E, Ciarrocchi E, Cerello P, Clozza A, Colombi S, De Lellis G, Del Guerra A, De Simoni M, Di Crescenzo A, Donetti M, Dong Y, Durante M, Embriaco A, Emde M, Faccini R, Ferrero V, Ferroni F, Fiandrini E, Finck C, Fiorina E, Fischetti M, Francesconi M, Franchini M, Galli L, Gentile V, Hetzel R, Hild S, Iarocci E, Ionica M, Kanxheri K, Kraan AC, Lante V, Lauria A, La Tessa C, Lopez Torres E, Massimi C, Marafini M, Mengarelli A, Mirabelli R, Montesi MC, Morone MC, Morrocchi M, Muraro S, Narici L, Pastore A, Pastrone N, Patera V, Pennazio F, Placidi P, Pullia M, Ramello L, Ridolfi R, Rosso V, Rovituso M, Sanelli C, Sartorelli G, Sato O, Savazzi S, Scavarda L, Schiavi A, Schuy C, Scifoni E, Sciubba A, Secher A, Selvi M, Servoli L, Silvestre G, Sitta M, Spighi R, Spiriti E, Sportelli G, Stahl A, Tomassini S, Tommasino F, Traini G, Toppi M, Valeri T, Valle SM, Vanstalle M, Villa M, Weber U, Zoccoli A, Sarti A. Measurement of 12C Fragmentation Cross Sections on C, O, and H in the Energy Range of Interest for Particle Therapy Applications. IEEE Trans Radiat Plasma Med Sci 2020. [DOI: 10.1109/trpms.2020.2972197] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
2
|
Fabbri L, Ridolfi R, Riccobon A, Maltoni R, Flamini E, Fedriga R, Flamigni A, Migliori G, Ortolani F, Calzolari F. Liver Metastases from Gastric Carcinoma: Report of a Patient Treated with Adoptive Immunotherapy (Tumor-Infiltrating Lymphocytes plus Interleukin-2 and Subsequently Local-Regional Lymphokine-Activated Killer Cells plus inTerleukin-2). Tumori 2018; 81:445-9. [PMID: 8804474 DOI: 10.1177/030089169508100613] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
A 37-year-old patient with liver metastases from gastric cancer was treated with a double adoptive immunotherapy regimen comprising tumor-infiltrating lymphocytes plus interleukin-2 and subsequently local-regional lymphokine-activated killer cells plus interleukin-2 because of an extremely high in vitro cytotoxic specific activity on established gastric cancer cell lines. The necrosis verified in the center of the hepatic metastasis would appear to demonstrate treatment efficacy, but no clinical response was seen. In vitro cytotoxicity data alone are insufficient to predict the clinical efficacy of adoptive immunotherapy.
Collapse
Affiliation(s)
- L Fabbri
- Istituto Oncologico Romagnolo, Forlì, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Ridolfi R, Casadei Giunchi D, Cortesi C, Maltoni M, Ravaioli A, Amadori D. A Retrospective Study of Fam Regimen in 38 Patients with Advanced Gastric Cancer. Tumori 2018; 70:375-9. [PMID: 6548054 DOI: 10.1177/030089168407000413] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Gastric carcinoma has a very poor prognosis, with a survival rate at 5 years of 13 %. Various chemotherapy regimens have been used in the advanced stages of the disease. The best results were obtained using the FAM combination. We treated 38 patients with advanced measurable gastric cancer using the FAM combination and obtained 23.67 % complete plus partial remission (CR+PR) (32 % with more restrictive criteria for eligible patients) and 34 % no change. The median length of response was 30 weeks in CR patients (range 20–100) and 26 weeks (range 12–34) in PR patients. Responsive patients (CR+PR) had a median survival of 12.3 months (range 5–22) compared to nearly 4 months (range 2–8) for unresponsive patients.
Collapse
|
4
|
Amadori D, Ravaioli A, Maltoni M, Ridolfi R, Gentilini P, Giunchi DC, Frassineti L, Falcini F, Amadori M. Combination Chemotherapy in Advanced Ovarian Carcinoma. Tumori 2018; 72:519-24. [PMID: 3798574 DOI: 10.1177/030089168607200513] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Ovarian carcinoma is the fifth most common cause of death among women in western countries. It is often diagnosed in an advanced stage (FIGO Stage III and IV) and requires effective chemotherapy as first-line treatment. The advent of cisplatin combined with adriamycin and cyclophosphamide has remarkably increased the response rate in advanced disease. The authors report 31 cases of epithelial ovarian neoplasia, without prior chemotherapy, treated with cisplatin, adriamycin and cyclophosphamide (PAC I). Of the 30 evaluable patients, 15 had clinical complete remissions (cCR = 50%), 10 clinical partial remissions (cPR = 33%) and 5 no response (NR = 17%). The total response (cCR + cPR) was equal to 83%. Twelve of the 15 patients in cCR underwent second-look laparotomy; in 8 of these cases, histologic and cytologic confirmation of CR was obtained. PAC I was found to be a highly effective therapeutic regimen with moderate toxicity. The individual toxicity reported was gastroenteric (nausea and vomiting), but transitory. No chronic toxic side-effects from cisplatin or adriamycin were noted. However, more definitive results must be obtained to verify its impact on the prolongation of survival.
Collapse
|
5
|
Amadori D, Ravaioli A, Gardini A, Liverani M, Zoli W, Tonelli B, Ridolfi R, Gentilini P. N-Nitroso Compound Precursors and Gastric Cancer: Preliminary Data of a Study on a Group of Farm Workers. Tumori 2018; 66:145-52. [PMID: 7445096 DOI: 10.1177/030089168006600202] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
An epidemiological research on gastric cancer mortality rates carried out in the town of Forlì is reported. The results are significant as regards the relation between the urban and rural areas, and show a higher risk for gastric cancer in the rural area. Salivary nitrite measurement in 92 farm workers showed particularly high values (over 30 ppm in 4 individuals). Analysis of histological findings in biopsies performed during endoscopy in 46 persons of the group studied showed a great number of CAG and CAG + IM in asymptomatic individuals.
Collapse
|
6
|
Fabbri M, Ridolfi R, Maltoni R, Ridolfi L, Riccobon A, Flamini E, De Paola F, Verdecchia GM, Amadori D. Tumor Infiltrating Lymphocytes and Continuous Infusion Interleukin-2 after Metastasectomy in 61 Patients with Melanoma, Colorectal and Renal Carcinoma. Tumori 2018; 86:46-52. [PMID: 10778766 DOI: 10.1177/030089160008600109] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
AIMS AND BACKGROUND Adoptive immunotherapy with tumor infiltrating lymphocyte (TIL) reinfusion plus continuous interleukin-2 (IL-2) infusion could represent an innovative way of treating immunogenic tumors. This study therefore recruited melanoma, colorectal and renal carcinoma patients whose metastases had been surgically removed. STUDY DESIGN The treatment was initially given to 22 patients with advanced disease and more recently to 39 disease-free (DF) patients after radical metastasectomy. The latter group was selected in view of a theoretically better lymphocyte/tumor cell ratio and with the aim to improve disease-free and overall survival (DFS-OS) in very high risk patients. The starting IL-2 dose was 12 MIU/day (West's schedule); doses were modulated on the bases of toxicity parameters. Even though patients received different total amounts of IL-2, all of them completed the treatment. RESULTS The treatment was offered to 22 advanced-stage cancer patients (12 melanomas, 9 colorectal carcinomas, 1 kidney carcinoma). Few and short stabilizations were observed with a median survival of 12 months (range, 3-29). Subsequently, another 39 patients were treated in an adjuvant setting after radical metastasectomy (18 melanomas, 19 colorectal carcinomas, 2 kidney cancers). Eleven out of 17 DF melanoma patients (64.7%) are still free of disease after a median of 37+ months (range, 5+ - 69+). In the group of DF colorectal cancer patients eight (44.4%) are still DF after a median of 21+ months (range, 7+ - 67+ months). One of the two patients with kidney cancer is still DF after 28+ months. Two patients (1 melanoma and 1 colorectal cancer) had just been treated and were therefore not evaluable. Severe toxicity occurred in three cases but was rapidly resolved. There was a great diversity in IL-2 doses administered; comparison of the total IL-2 dose administered between the patients who are still DF and those who progressed revealed no difference between the two groups of colorectal cancer patients, whereas melanoma patients who progressed received an average IL-2 dose of 6.5 MIU/day versus 15.8 MIU/day in DF patients. No differences were observed in any of the groups between the number of TILs reinfused and clinical response. CONCLUSIONS The study is still ongoing; it has been decided to focus on DF melanoma patients after radical metastasectomy, for whom the data seem to be encouraging. Further endpoints of the study are the role of IL-2 dosage in the adjuvant setting, and the possibility to make correlations between biological parameters and clinical results.
Collapse
Affiliation(s)
- M Fabbri
- Istituto Oncologico Romagnolo, Forlì, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Gutzmer R, Rivoltini L, Levchenko E, Testori A, Utikal J, Ascierto PA, Demidov L, Grob JJ, Ridolfi R, Schadendorf D, Queirolo P, Santoro A, Loquai C, Dreno B, Hauschild A, Schultz E, Lesimple TP, Vanhoutte N, Salaun B, Gillet M, Jarnjak S, De Sousa Alves PM, Louahed J, Brichard VG, Lehmann FF. Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. ESMO Open 2016; 1:e000068. [PMID: 27843625 PMCID: PMC5070281 DOI: 10.1136/esmoopen-2016-000068] [Citation(s) in RCA: 50] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Accepted: 04/22/2016] [Indexed: 12/23/2022] Open
Abstract
Purpose The PRAME tumour antigen is expressed in several tumour types but in few normal adult tissues. A dose-escalation phase I/II study (NCT01149343) assessed the safety, immunogenicity and clinical activity of the PRAME immunotherapeutic (recombinant PRAME protein (recPRAME) with the AS15 immunostimulant) in patients with advanced melanoma. Here, we report the phase I dose-escalation study segment. Patients and methods Patients with stage IV PRAME-positive melanoma were enrolled to 3 consecutive cohorts to receive up to 24 intramuscular injections of the PRAME immunotherapeutic. The RecPRAME dose was 20, 100 or 500 µg in cohorts 1, 2 and 3, respectively, with a fixed dose of AS15. Adverse events (AEs), including predefined dose-limiting toxicity (DLT) and the anti-PRAME humoral response (ELISA), were coprimary end points. Cellular immune responses were evaluated using in vitro assays. Results 66 patients were treated (20, 24 and 22 in the respective cohorts). AEs considered by the investigator to be causally related were mostly grade 1 or 2 injection site symptoms, fatigue, chills, fever and headache. Two DLTs (grade 3 brain oedema and proteinuria) were recorded in two patients in two cohorts (cohorts 2 and 3). All patients had detectable anti-PRAME antibodies after four immunisations. Percentages of patients with predefined PRAME-specific-CD4+T-cell responses after four immunisations were similar in each cohort. No CD8+ T-cell responses were detected. Conclusions The PRAME immunotherapeutic had an acceptable safety profile and induced similar anti-PRAME-specific humoral and cellular immune responses in all cohorts. As per protocol, the phase II study segment was initiated to further evaluate the 500 µg PRAME immunotherapeutic dose. Trial registration number NCT01149343, Results.
Collapse
Affiliation(s)
- R Gutzmer
- Skin Cancer Center Hannover , Hannover Medical School , Hannover , Germany
| | - L Rivoltini
- Unit of Immunotherapy of Human Tumors , Fondazione RCCS Istituto Nazionale dei Tumori , Milan , Italy
| | - E Levchenko
- Petrov Research Institute of Oncology , St. Petersburg , Russia
| | - A Testori
- Istituto Europeo Di Oncologia , Milano , Italy
| | - J Utikal
- Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany
| | - P A Ascierto
- Melanoma, Cancer Immunotherapy and Innovative Therapies Unit , Istituto Nazionale Tumori Fondazione Pascale , Naples , Italy
| | - L Demidov
- Cancer Research Center , Moscow , Russia
| | - J J Grob
- Aix Marseille University Hôpital de la Timone, Service de Dermatologie , Marseille , France
| | - R Ridolfi
- Immunotherapy Unit , Romagna Cancer Institute IRST- IRCCS , Meldola , Italy
| | - D Schadendorf
- Department of Dermatology , University Hospital Essen , Essen , Germany
| | - P Queirolo
- Istituto Nazionale per la Ricerca sul Cancro Oncologia Medica , Genova , Italy
| | - A Santoro
- Humanitas Cancer Center, Istituto Clinico Humanitas IRCCS , Rozzano , Italy
| | - C Loquai
- Department of Dermatology , University of Mainz , Mainz , Germany
| | - B Dreno
- Dermatology Clinic , Hôpital Hôtel-Dieu, CHU Nantes , Nantes , France
| | - A Hauschild
- Department of Dermatology , Skin Cancer Center, Schleswig-Holstein University Hospital , Kiel , Germany
| | - E Schultz
- Department of Dermatology , Paracelsus Medical University, Klinikum Nuremberg , Nuremberg , Germany
| | - T P Lesimple
- Département d'Oncologie Médicale , Centre Eugène Marquis , Rennes , France
| | | | - B Salaun
- GSK Vaccines , Rixensart , Belgium
| | - M Gillet
- GSK Vaccines , Rixensart , Belgium
| | | | - P M De Sousa Alves
- GSK Vaccines, Rixensart, Belgium; Celyad, Mont-Saint-Guibert, Rixensart, Belgium
| | | | - V G Brichard
- GSK Vaccines, Rixensart, Belgium; Vianova-Biosciences, Lasne, Belgium
| | - F F Lehmann
- GSK Vaccines, Rixensart, Belgium; Celyad, Mont-Saint-Guibert, Rixensart, Belgium
| |
Collapse
|
8
|
Adovasio A, Aitini E, Ceppi M, Bruzzone M, Pisanelli B, Oliani C, Patruno E, Adami F, Ridolfi R, Gentilini P, Comella G, Castagneto B, Barni S, Labianca R, Crispino S, Porcile G, Gennaro V. Cancer Registries Underestimate both the Type of Disease and also Number of Cases due to Pollution. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Pegoraro M, Barana D, Schiavo G, Fracca I, Giabardo C, Forni C, Padovani M, Binato S, Magazù M, Aitini E, Adami F, Ridolfi R, Porcile G, Oliani C. Style modification in breast and Colorectal Cancer Patients: results of a pilot study Long-Survivors. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Adami F, Porcile G, Ridolfi R, Labianca R, Palazzo S, Bretti S, Gentilini P, Carbonardi F, Oliani C, Aitini E. Circulating microRNAs (miRNAs): Biomarkers for Lung Cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.42] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Ridolfi R, Gentilini P, Saletti A, Timoncini G, Burgio E, Porcile G, Gennaro V, Oliani C, Castagneto B, Lugano M, Adami F. No city for children. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv348.64] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
12
|
Di Giacomo A, Ascierto P, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M. Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. Ann Oncol 2015; 26:798-803. [DOI: 10.1093/annonc/mdu577] [Citation(s) in RCA: 103] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Maio M, Danielli R, Chiarion-Sileni V, Pigozzo J, Parmiani G, Ridolfi R, De Rosa F, Del Vecchio M, Di Guardo L, Queirolo P, Picasso V, Marchetti P, De Galitiis F, Mandalà M, Guida M, Simeone E, Ascierto PA. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol 2013; 24:2911-5. [PMID: 24067719 DOI: 10.1093/annonc/mdt376] [Citation(s) in RCA: 110] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Patients with advanced uveal melanoma have a poor prognosis and limited treatment options. Ipilimumab is approved for pre-treated adult patients with advanced melanoma. However, because previous clinical trials with ipilimumab have excluded patients with uveal melanoma, data in this patient population are limited. PATIENTS AND METHODS Pre-treated patients with advanced uveal melanoma received ipilimumab 3 mg/kg through an expanded access programme, every 3 weeks for four doses. Tumour assessments were conducted at baseline and after completion of treatment and patients were monitored throughout for adverse events. RESULTS Among 82 assessable patients, 4 (5%) had an immune-related objective response and 24 (29%) had immune-related stable disease lasting ≥3 months for an immune-related disease control rate of 34%. With a median follow-up of 5.6 months, median overall survival (OS) was 6.0 months and median progression-free survival (PFS) was 3.6 months. The 1-year rates of OS and PFS were 31% and 11%, respectively. The safety profile of ipilimumab was similar to that in patients with cutaneous melanoma. CONCLUSIONS These data suggest ipilimumab 3 mg/kg is a feasible option in pre-treated patients with metastatic uveal melanoma. Evidence of disease control and a 1-year survival rate of 31% indicate the need for further investigation in randomised, controlled trials to determine the optimal timing and use of ipilimumab in this patient population.
Collapse
Affiliation(s)
- M Maio
- Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Tuscan Cancer Institute, Siena
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Farolfi A, Ridolfi L, Guidoboni M, Milandri C, Calzolari F, Scarpi E, Amadori D, Ridolfi R. Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. J Chemother 2013; 23:300-5. [DOI: 10.1179/joc.2011.23.5.300] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
15
|
Maio M, Queirolo P, Testori A, Altomonte M, Maur M, Bajetta E, Ascierto P, Sileni VC, Di Giacomo A, Ridolfi R. Safety and Efficacy of Ipilimumab 10 Mg/Kg Among Patients with Advanced Melanoma from Italy Enrolled in a European Compassionate Use Program. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33703-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
16
|
Pi Giacomo A, Ascierto P, Pittiglio E, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Parmiani G, Maio M. 9305 ORAL A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma – the NIBIT-M1 Trial. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72514-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
17
|
Correale P, Rotundo M, Botta C, Guglielmo A, Licchetta A, Conca R, Tassone P, Ridolfi R, Mini E, Tagliaferri P. 6106 POSTER Immune-boost Treatment With Gemcitabine, Oxaliplatin, Levofolinate, 5-flurouracil, Granulocyte/macrophage Colony-stimulating-factor (GM-CSF) and Aldesleukine Enhances Progression-free and Overall-survival Over FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients – Early Results From the GOLFIG-2 Phase III Trial. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71751-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
18
|
Petrini M, Ridolfi L, Fiammenghi L, Napolitano M, Granato AM, Ancarani V, Pancisi E, Guidoboni M, Nicoletti S, Valmorri L, Riccobon A, Migliori G, Venanzi FM, Ascierto PA, Ridolfi R. Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e13029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Di Giacomo AM, Ascierto PA, Fonsatti E, Pittiglio E, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Parmiani G, Maio M. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: The NIBIT-M1 trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps230] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Ridolfi L, Vannini I, Fanini F, Fiammenghi L, Petrini M, Ancarani V, Granato AM, Guidoboni M, Pancisi E, Riccobon A, Ridolfi R, Fernandez-Cymering C, Volinia S, Milandri C, Croce CM, Fabbri M. Use of microRNA signature to predict patient sensitivity to dendritic cell vaccination in metastatic melanoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8591] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Chiarion-Sileni V, Guida M, Romanini A, Ridolfi R, Mandala M, Del Bianco P, Silvestri B, Medici M, Michiara M, Dalla Palma M, Puccetti O, Pigozzo J, Laveder F, De Salvo GL. Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.8506] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Ricci M, Pirotti S, Burgio M, Scarpi E, Sansoni E, Ridolfi R, Amadori D, Maltoni M. Safety and efficacy of Scrambler therapy for cancer pain. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19591] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Ridolfi L, Fiammenghi L, Petrini M, Granato A, Ancarani V, Pancisi E, Guidoboni M, Riccobon A, Ascierto PA, Ridolfi R. Low-dose temozolomide modulation of peripheral blood regulatory T cells before dendritic cell-based vaccination in metastatic melanoma: Phase I/II study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Guida M, Muggiano A, Albano D, Ridolfi R, Testori A, Chiarion-Sileni V, Sertoli MR, Romanini A, Parmiani G, Colucci G. Improved survival for stage III/IV melanoma from an unknown primary site (MUP): An Italian multicentric study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Altomonte M, Queirolo P, Testori A, Ascierto P, Danielli R, Giacomo AD, Sileni VC, Del Vecchio M, Ridolfi R, Maio M. 9328 The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71972-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
26
|
Schmidt H, Hamid O, Nissan A, Guida M, Aamdal S, Hansson J, Ridolfi R, Berman D, Chasalow S. 9304 Identification of tumor biopsy markers as potential predictors of ipilimumab clinical activity in patients with advanced melanoma. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71948-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
27
|
Procopio G, Verzoni E, Bracarda S, Ricci S, Miceli R, Bertolini A, Porta C, Ridolfi R, Zilembo N, Bajetta E. 7107 A randomized, prospective, Phase 2 study, with Sorafenib (So) and Interleukin-2 (IL-2) versus So alone as first line treatment in advanced Renal Cell Cancer (RCC): ROSORC Trial. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71440-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Danielli R, Queirolo P, Testori A, Plummer R, Razi E, Sileni VC, Calabrò L, Giacomo AD, Ridolfi R, Maio M. 9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71959-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
29
|
Ballardini M, Ridolfi L, Bertetto O, Santo A, Naglieri E, Lopez M, Recchia F, Lissoni P, Fumagalli L, Ridolfi R. Italian multicentric trial comparing chemotherapy with or without low-dose interleukin-2 (IL-2) in advanced non-small cell lung cancer: Results from a phase III randomized study. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8019 Background: Non small cell lung cancer (NSCLC) is associated with an IL-2-dependent cell-mediated immunodeficiency, and lymphocyte count is considered an independent prognostic factor as it seems to correlate with overall survival. A phase III randomized Italian multicentric trial was conducted to evaluate the efficacy of subcutaneous low-dose IL-2 added to standard CT on overall survival (OS) in advanced NSCLC patients. Methods: Histologically/cytologically confirmed stage IIIb or IV non operable NSCLC patients with measurable disease, ECOG PS 0–2, age 18–70 years and adequate bone marrow, renal and liver function were eligible for the study. Randomization was stratified by center, ECOG PS, stage of disease and percentage of weight loss. All patients received gemcitabine (1000mg/m2) on days 1 and 8 + cisplatin (100mg/m2) on day 2 every 21 days for a maximum of 6 cycles (CT arm). In the CT+IL-2 arm, patients also received low-dose subcutaneous IL-2 3,000,000 IU/die on days 3–5; 9–11; 15–17. The study had 90% power to detect a 20% absolute increase in 1-year OS with 120 patients per arm. Results: From June 2000 to October 2004, 241 patients were randomized (arm A/B: 127/114). At a median follow up of 32 months, 1-year OS was 45% for the CT+IL-2 arm vs. 51% for the CT arm (p=0.456 logrank). Median progression-free survival was 6.6 months in the CT+IL-2 arm vs. 6.9 months in the CT arm (p=0.573, logrank). Conclusions: The study did not show any relevant difference in clinical outcome by the addition of IL-2 to CT. Safety and subgroup analyses are ongoing to verify the efficacy of IL-2 as a function of clinical and biological characteristics of patients and tumors. Future studies to investigate the role of T-regulators in chemoimmunotherapy strategies, unknown when the study was originally planned, could be conducted. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Ballardini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - L. Ridolfi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - O. Bertetto
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - A. Santo
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - E. Naglieri
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - M. Lopez
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - F. Recchia
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - P. Lissoni
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - L. Fumagalli
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| | - R. Ridolfi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy; Le Molinette Hospital, Turin, Italy; University of Verona, Borgo Trento Hospital, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hospital, Avezzano, Italy; San Gerardo Hospital, Monza, Italy
| |
Collapse
|
30
|
Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Valmorri L, Riccobon A, Ridolfi R. Dendritic cell vaccination in melanoma patients: Update and subgroup analysis of clinical response to post-vaccine treatment. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.9042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
9042 Background: Dendritic cells (DCs) play a crucial role in the interplay between innate and adaptive immune response towards cancer. The combination of immunotherapies with standard treatments for cancer could represent a further chance for advanced melanoma patients. In the literature, higher response rates than those normally obtained have been reported after second-line chemotherapy in patients with non small cell lung cancer pre-treated with vaccines and in patients with follicular B-cell lymphoma vaccinated with an anti-idiotype vaccine whilst in remission. On the basis of this data, we reviewed and updated the clinical results of our dendritic cell based vaccine clinical trial in stage IV melanoma patients. Methods: From December 2002 to 2007, 24 pre-treated metastatic melanoma patients were vaccinated with mature DCs (mDCs) pulsed with autologous tumor lysate (ATL) and keyhole limpet hemocyanin (KLH) followed by a 5-day treatment with low-dose subcutaneous Interleukin-2. Results: We observed 2 complete response (CR), 2 mixed response (MR), 5 partial response (PR), 4 stable disease (SD) and 11 progressive disease (PD) (overall response (OS) 37.5%; clinical benefit 54.1%). All 13 responders had delayed-type hypersensitivity (DTH) positivity to KLH, of whom 10 also showed positivity to the lysate. Eleven (45.8%) of the 24 patients underwent further lines of treatment (5 chemotherapy [CT], 3 surgery [S], 4 biotherapy, 2 radiotherapy [RT] and 4 biochemotherapy [BioCT]) after stopping vaccination (8 due to progression and 3, in SD, because all of their lysate had been used). Of these 11 patients, 2 obtained CR (1 RT, 1 S), 5 PR (3 BioCT, 2 S) for an OR of 63.6%, 1 SD (BioCT) and 3 showed PD as the best response to subsequent therapies, with a median OS of 30 months (range 16–52). Of the 3 SD patients who were forced to stop vaccine treatment, 1 had CR following RT and 2 progressed. Conclusions: Metastatic melanoma responds poorly to standard therapy, in particular after first-line treatment. Vaccination could enhance clinical response to subsequent third- or fourth-line therapies, thus prolonging overall survival. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- L. Ridolfi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - L. Fiammenghi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - M. Petrini
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - A. M. Granato
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - V. Ancarani
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - E. Pancisi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - L. Valmorri
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - A. Riccobon
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| | - R. Ridolfi
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola-Forlì, Italy
| |
Collapse
|
31
|
|
32
|
Venanzi F, Riccobon A, Gabrielli F, Petrini M, Fiammenghi L, Granato AM, Bolli E, Ridolfi L, Concetti A, Ridolfi R. Dendritic cell (DC) antitumor vaccine: TEM8 expression in matured DC identifies clinical responders. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Weber JS, Berman D, Siegel J, Minor D, Amin A, Thompson JA, Ron I, Ridolfi R, Assi H, Hamid O. Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9010] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
34
|
Chiarion-Sileni V, Guida M, Ridolfi R, Romanini A, Brugnara S, Del Bianco P, Perfetti E, Cavallo R, Pigozzo J, Donati D, De Salvo G. Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Thompson JA, Berman D, Siegal J, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Hamid O, Weber J. Effect of prior treatment status on the efficacy and safety of ipilimumab monotherapy in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.9055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Ridolfi R, Andreis D, Panzieri M, Ceccherini F. The application of environmental certification to the Province of Siena. J Environ Manage 2008; 86:390-5. [PMID: 17064839 DOI: 10.1016/j.jenvman.2006.04.013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/31/2005] [Revised: 02/03/2006] [Accepted: 04/05/2006] [Indexed: 05/12/2023]
Abstract
The SPIn-Eco project has provided very broad and precise data collection regarding the Province of Siena. These data and their elaborations have also been developed as a basis for the environmental certification of this organization. In this way, the Administration of the Province of Siena (the first Province in Italy) has reached its goal of obtaining better knowledge of the state of the system and of constructing its environmental management system (EMS) according to the environmental aspects directly and indirectly arising from the organization's activities. Indirect aspects are mainly related to the territorial monitoring and planning. Indicators based on the classical pressure-state-response approach, as well as more complex ones based on CO(2) balance, emergy and ecological footprint analyses, have been used to assess the environmental performance of the EMS. This paper presents how this EMS is constructed, as well as the indicators that are used to analyze the system, paying particular attention to sustainability indicators.
Collapse
Affiliation(s)
- R Ridolfi
- Department of Chemical and Biosystems Sciences, University of Siena, Via Aldo Moro 2, 53100, Siena, Italy.
| | | | | | | |
Collapse
|
37
|
Ridolfi R, Kneller M, Donati A, Pulselli RM. The greenhouse gas balance of the Province of Siena. J Environ Manage 2008; 86:365-71. [PMID: 17056175 DOI: 10.1016/j.jenvman.2006.04.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2005] [Revised: 02/02/2006] [Accepted: 03/05/2006] [Indexed: 05/12/2023]
Abstract
There is a profound debate over how to assign greenhouse gas (GHG) responsibilities; therefore, we have decided to follow IPCC guidelines, as they offer the only standardized method. We have identified each type of greenhouse emission and its level of absorption. We have studied the province and its districts and municipalities. We have determined that the energy sector is that with the highest level of emissions, even if the per capita emissions of the Province of Siena are very low. This is caused by a very low level of industrialization and the presence of a local geothermal production of energy. In order to highlight this aspect, we have considered scenarios both with and without geothermal production. Our research was then focused on single districts (groups of homogenous municipalities) and municipalities, where we found great differences among the greenhouse emissions of the areas. We have constructed a map of the greenhouse emissions of the whole province. It has been interesting to note that there are 14 municipalities with net negative emissions, seven with low positive emissions, 12 with medium positive emissions and three with elevated positive emissions. These latter correspond to the main city and to two of the most industrialized municipalities.
Collapse
Affiliation(s)
- R Ridolfi
- Department of Chemical and Biosystems Sciences, University of Siena, Via Aldo Moro 2, Siena 53100, Italy.
| | | | | | | |
Collapse
|
38
|
Marchettini N, Ridolfi R, Rustici M. An environmental analysis for comparing waste management options and strategies. Waste Manag 2007; 27:562-71. [PMID: 16765586 DOI: 10.1016/j.wasman.2006.04.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/28/2005] [Revised: 12/13/2005] [Accepted: 04/18/2006] [Indexed: 05/10/2023]
Abstract
The debate on different waste management practices has become an issue of utmost importance as human activities have overloaded the assimilative capacity of the biosphere. Recent Italian law on solid waste management recommends an increase in material recycling and energy recovery, and only foresees landfill disposal for inert materials and residues from recovery and recycling. A correct waste management policy should be based on the principles of sustainable development, according to which our refuse is not simply regarded as something to eliminate but rather as a potential resource. This requires the creation of an integrated waste management plan that makes full use of all available technologies. In this context, eMergy analysis is applied to evaluate three different forms of waste treatment and construct an approach capable of assessing the whole strategy of waste management. The evaluation included how much investment is needed for each type of waste management and how much "utility" is extracted from wastes, through the use of two indicators: Environmental yield ratio (EYR) and Net eMergy. Our results show that landfill is the worst system in terms of eMergy costs and eMergy benefits. Composting is the most efficient system in recovering eMergy (highest EYR) from municipal solid waste (MSW) while incineration is capable of saving the greatest quantity of eMergy per gram of MSW (highest net eMergy). This analysis has made it possible to assess the sustainability and the efficiency of individual options but could also be used to assess a greater environmental strategy for waste management, considering a system that might include landfills, incineration, composting, etc.
Collapse
Affiliation(s)
- N Marchettini
- Department of Chemical and Biosystems Sciences, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy
| | | | | |
Collapse
|
39
|
Nanni O, Serra P, Tison C, De Castro M, Ridolfi R, Falcini F, Amadori D, Erroi V, Meggiolaro E. Survey of the sociodemographic and motivational profile of volunteers in oncology. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.16011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16011 Background: The volunteer sector developed rapidly in Italy throughout the 1980s, especially in the areas of cancer and palliative care. Istituto Oncologico Romagnolo (IOR), a non profit organization based in Forlì, actively supports the public health sector in the fight against cancer by funding scientific research, organizing voluntary work, promoting education campaigns, and setting up prevention and screening programs. The aim of the present work is to trace a sociodemographic and motivational profile of IOR volunteers. Methods: In May 2005, all IOR volunteers were invited to complete an anonymous questionnaire composed of 12 structured questions designed to collect sociodemographic data, information on type of voluntary work done and the reasoning behind such a choice. Results: Of IOR’s 1043 volunteers, 471 completed the questionnaire, of whom 70% were female and about one-third over 65 years of age. The majority of professions were represented, even though about two-thirds of men and half of the female volunteers were retired. About 40% of the group had been doing voluntary work for more than 10 years. Although fund-raising proved to be the most frequent activity (80%), there is a growing number of volunteers, especially those of a younger age group, involved in home- and hospital-based care. Various reasons were given for becoming a IOR volunteer: ethical considerations (35 % males and 28% females), personal experiences (24% and 38%, respectively), high regard held for IOR and its work (31 and 26%, respectively), and involvement directly through other volunteers (29 and 36%, respectively). Conclusions: The major involvement in fund-raising and perseverance over time of volunteers indicate a favorable social perception of medical research. It also emerged that the decision to start voluntary work was often closely linked to a previous personal experience of loss or disease, especially in female volunteers, who tend to react more constructively and develop a more active and concrete solidarity than men. We can therefore conclude that volunteers in the area of cancer act out of a sense of responsibility and awareness rather than out of pity or a desire for self-gratification. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- O. Nanni
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - P. Serra
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - C. Tison
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - M. De Castro
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - R. Ridolfi
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - F. Falcini
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - D. Amadori
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - V. Erroi
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| | - E. Meggiolaro
- Istituto Oncologico Romagnolo, Forlì, Italy; Pierantoni Hospital, Forlì, Italy; Cancer Prevention Unit of Pierantoni Hospital, Forlì, Italy; IRST, Meldola, Italy
| |
Collapse
|
40
|
Ridolfi R, Matera L, Tizzani A. Immunotherapy for Urologic Tumors. Urologia 2006. [DOI: 10.1177/039156030607300401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cancer vaccines are intended to promote a long-lasting memory response against tumors. Rationale for cancer vaccines is based on two observations: a) many tumors express antigens (TA), which are recognized by specific cytotoxic T lymphocytes; b) these lymphocytes may protect the host against tumor growth in vivo. So far, cancer vaccines have been developed using soluble TA and, more recently, TA presented by dendritic cells (DC), the most powerful antigen presenting cells (APC). DCs play a key role in the process leading to antigen recognition and lymphocyte activation. Despite a deeper understanding of these processes, clinical efficacy of cancer vaccines is still hampered by the heterogeneity of the studies performed so far, and by the largely unknown mechanisms through which tumors escape immunosurveillance. Current DC-based cancer vaccines require the preparation of DCs from patient blood monocytes, as well as DC-loading with TA. Both whole tumor and TA peptides are used as source of TA. Similar schedules have been implemented in many clinical trials on melanoma, kidney and prostate cancer, with partial responses ranging from 7% to 30%. The study population was made up of non-respondent patients to any other therapy; the DC vaccination showed an extremely low toxicity. 22 patients with metastatic melanoma received a DC vaccine in Forlì (Italy) since August 2001. Good correlation between immunologic response, clinical response and overall survival was found. A clinical trial on pulsed APC administration to patients with recurring prostate cancer is ready to be started in Torino (Italy), pending the Ministerial approval from a local cell factory.
Collapse
Affiliation(s)
- R. Ridolfi
- Dipartimento di Oncologia Medica, Istituto Oncologico Romagnolo-IRST, Forlì
| | - L. Matera
- Laboratorio Immunologia dei Tumori, Dipartimento Medicina Interna
| | - A. Tizzani
- I Clinica Urologica, Università degli Studi di Torino
| |
Collapse
|
41
|
Ridolfi R, Dall’agata M, Bertetto O, Santo A, Naglieri E, Lopez M, Recchia F, Lissoni P, Porcile G, Fumagalli L, Nanni O. Randomized Italian multicentric trial comparing cisplatinum and gemcitabine with or without low dose interleukin-2 (IL-2) in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Ridolfi
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - M. Dall’agata
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - O. Bertetto
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - A. Santo
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - E. Naglieri
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - M. Lopez
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - F. Recchia
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - P. Lissoni
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - G. Porcile
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - L. Fumagalli
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| | - O. Nanni
- Morgagni-Pierantoni Hosp, Forlì, Italy; Inst Oncologico Romagnolo, Forlì, Italy; Le Molinette Hosp, Turin, Italy; Univ of Verona, Borgo Trento Hosp, Verona, Italy; IRCCS, Bari, Italy; Polo Oncologico IFO San Raffaele, Rome, Italy; Avezzano Hosp, Avezzano, Italy; San Gerardo Hosp, Monza, Italy; San Lazzaro Hosp, Alba, Italy
| |
Collapse
|
42
|
Milandri M, Calzolari F, Passardi A, Ridolfi R, Tison C, Giampalma E, Golfieri R, Ridolfi L, Mura G, Vagliasindi A, Fra Marini M, Verdecchia GM. Intra-arterial chemotherapy for liver metastases from colorectal cancer. Suppl Tumori 2005; 4:S45. [PMID: 16437895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
The aim was to investigate whether intra-arterial infusion of chemotherapy improves response to treatment in unresectable liver metastases from colorectal cancer. We treated 14 patients (pts) with intra-arterial chemotherapy. Arterial catheters were placed via percutaneous access. Treatment schedule was: 5-FU and mitomycin-C on day 1 every 21 days. Six pts also received from day 3 for 5 days, a continuous intra-arterial 24-hr infusion of interleukin-2 (IL-2). We had only one case of toxicity drug-related > grade 2 (neutropenia). We observed 2 partial response (PR) and 5 stable disease (SD). Median time to disease progression (TTP) and median survival (OS) were, respectively 4 and 15 months.
Collapse
Affiliation(s)
- M Milandri
- UO Oncologia Medica, Ospedale Morgagni-Pierantoni, Forlì
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Ibrahim T, Riccobon A, Petrini M, Stefanelli M, Tison C, Ridolfi R, Amadori D. The role of serum chromogranin A (CgA) in patients with small cell lung cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Ibrahim
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| | - A. Riccobon
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| | - M. Petrini
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| | - M. Stefanelli
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| | - C. Tison
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| | - R. Ridolfi
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| | - D. Amadori
- Pierantoni Hospital, Dept of Medical Oncology, Forli (FC), Italy; Istituto Oncologico Romagnolo, Forli (FC), Italy
| |
Collapse
|
44
|
Ridolfi R, Riccobon A, Petrini M, Ridolfi L, Fiammenghi L, Stefanelli M, Selva M, Amadori D. Comparison between immature and mature dendritic cells in a vaccination trial. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Ridolfi
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - A. Riccobon
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - M. Petrini
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - L. Ridolfi
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - L. Fiammenghi
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - M. Stefanelli
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - M. Selva
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| | - D. Amadori
- Pierantoni Hospital, Dept of Medical Oncology, Forli, Italy; Istituto Oncologico Romagnolo, Forli, Italy; Morgagni Hospital, Blood Transfusion Unit, Forli, Italy
| |
Collapse
|
45
|
Serrone L, Freschi A, Chiarion-Sileni V, Ridolfi R, Toma S, Guida M, Cognetti F. Radiotherapy followed by temozolomide in the treatment of patients with melanoma metastatic to the brain: An Italian multicentre study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7558] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- L. Serrone
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| | - A. Freschi
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| | - V. Chiarion-Sileni
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| | - R. Ridolfi
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| | - S. Toma
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| | - M. Guida
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| | - F. Cognetti
- Istituto Regina Elena, Roma, Italy; Istituto Nazionale Tumori, Aviano, Italy; Azienda Ospedaliera, Padova, Italy; Ospedale Morgagni-Pierantoni, Forlì, Italy; Istituto Nazionale Tumori, Genova, Italy; Istituto Nazionale Tumori, Bari, Italy
| |
Collapse
|
46
|
Riccobon A, Ridolfi R, Galassi R, Petrini M, Stefanelli M, Fiammenghi L, Giorgetti G, Moretti A, Ridolfi L, Fiorentini G. Cancer Cell Int 2004; 4:S15. [DOI: 10.1186/1475-2867-4-s1-s15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
47
|
Verdecchia GM, Ridolfi L, Ridolfi R, Riccobon A, Bertagni A, Vagliasindi A, Petrini M, Stefanelli M, Milandri C, Amadori D. [Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]. Tumori 2003; 89:298-300. [PMID: 12903626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
Adoptive immunotherapy trials with tumor infiltrating lymphocytes (TIL) and interleukin-2 (IL-2) were carried out in the treatment of advanced melanoma with a 34% of overall responses (OR). However, theoretically it should be of greater benefit as adjuvant therapy, especially in high-risk stages (stage III and resected stage IV). In a pilot study, 22 patients (aged 23-72 years) with stage III-IV melanoma who underwent radical metastasectomy were reinfused with TIL cultivated and expanded in vitro with IL-2 from surgically removed metastases. IL-2 (starting dose 12 x 10(6) IU/m2) was co-administered as a continuous infusion according to West's scheme. A total of 8/22 (36.3%) patients were disease-free (DF) at a median follow-up of 5 years. DF survival (DFS) and overall survival (OS) in the remaining 14 patients were 44% and 37% and 52% and 45% at 2 and 3 years, respectively. The CNS was the only site of disease recurrence in 57% of patients who relapsed. DF patients received a higher median dose of IL-2 than those who progressed (total dose 110 x 10(6) vs 86 x 10(6) IU/m2, respectively). The progressive reduction in IL-2 dosage allowed all patients to complete treatment without permanent grade 4 toxicity. The effects of tumor immunosuppression in lymphocytes inside the tumor (TCR z and e chains, p56lck, FAS and FAS-ligand) confirmed that the potential function of TIL, immunodepressed at the time of metastasectomy, was significantly restored after in vitro, culture with IL-2. Adjuvant adoptive immunotherapy with TIL and IL-2 seems to improve DFS and OS, in comparison with literature data. Further studies are required to determine its role in the adjuvant treatment of patients with high-risk melanoma.
Collapse
|
48
|
Milandri C, Calzolari F, Giampalma E, Vagliasindi A, Bertagni A, Ridolfi L, Passardi A, Ridolfi R, Golfieri R, Verdecchia GM. [Combined treatment of inoperable liver metastases from colorectal cancer]. Tumori 2003; 89:112-4. [PMID: 12903565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/04/2023]
Abstract
AIMS Liver resection improves survival in selected patients with colorectal liver metastases. However, the majority of patients with colorectal liver metastases have an inoperable oncological disease. The aim is to investigate whether intra-arterial infusion of chemotherapy, improves response to treatment and may convert a selected group of patients with irresectable liver metastases into an operable state. MATERIALS AND METHODS Thirty-sex patients (pts) with inoperable hepatic metastases from colorectal cancer were treated with intra-arterial chemotherapy, by angiographic technique. All patients underwent a short 5-FU-based locoregional infusion and the 13 non pretreated patients also received systemic therapy. Evaluation of response was made by CT scan. RESULTS Total cycles administered angiographically: 132 (range, 1-11). There were no complications associated with the angiographic procedure and no cases of > grade 2 toxicity. One heavily pretreated pt experienced moderate cholangitis and superficial gastric erosion. Thirty-one pts were assessable (20 pretreated and 11 not); there was 1 complete response (CR), 3 partial remissions (PR), 2 stabilizations (SD) among non-pretreated pts (6/11; CR + PR + SD = 55%) and 1 PR and 8 SD among pretreated pts (9/20; PR + SD = 45%). The remaining 16 pts progressed. Four pts became eligible for radical hepatic resection (1 refused surgery and 3 patients were operated on). There was no peri-operative deaths. Median survival of these 3 pts was 24, 28 and 39+ months. CONCLUSIONS Our data, even if based on a relatively small case series, appear to confirm effective local disease control in this clinical setting. Regional chemotherapy used singly or in combination with systemic chemotherapy may convert a selected group of patients with irresectable liver metastases to an oncological disease that can benefit from surgical treatment.
Collapse
Affiliation(s)
- C Milandri
- Dipartimento di Oncologia Medica, Generale II, Unità di Chirurgia Oncologica Avanzata
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, Nortilli R, Corgna E, Dalla Palma M, Lo Presti G, Ridolfi R. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003; 39:1577-85. [PMID: 12855265 DOI: 10.1016/s0959-8049(03)00372-1] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
This study analyses the health related quality of life (HRQOL) of advanced melanoma patients, in a randomised trial comparing bio-chemotherapy (bio-CT) versus chemotherapy (CT). The trial enrolled 178 patients and the median survival was not statistically different between the two arms. HRQOL was assessed at baseline and before each cycle of therapy, using the Rotterdam Symptom Checklist (RSCL) questionnaire completed with 140 patients. At baseline, overall quality of life and psychological distress scores were the most impaired, compared with the normal population. During treatment, the difference between the two arms in the changes from baseline was statistically significant (P=0.03) only in the overall quality of life score, with a decrease of 6.28 points in the bio-CT arm. The mean values decreased significantly in all domains in bio-CT arm, but only in activity level and physical symptom distress scores in the CT arm. Testing HRQOL variables and prognostic clinical factors in a Cox model, only the serum level of lactic dehydrogenase, baseline overall quality of life and the physical symptom distress scores remained significant independent prognostic factors for survival. A score of less than 75 points in the overall quality of life and in the physical symptom distress domains was associated with a Hazard Ratio (HR) of 2.31 (95% Confidence Interval (CI): 1.09-4.90) and 1.92 (95% CI: 1.10-3.36), respectively.
Collapse
Affiliation(s)
- V Chiarion-Sileni
- Department of Medical Oncology, Padova University Hospital, Via Gattamelata 64, 35128 Padova, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Ridolfi R, Tanganelli L, Scelzi E, Manente P, Palmeri S, Ravaioli A, Fiammenghi L, Romanini A. Chemotherapy and bio-chemotherapy in patients with advanced melanoma: combination therapy with a nitrosourea. J Chemother 2003; 15:198-202. [PMID: 12797399 DOI: 10.1179/joc.2003.15.2.198] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
The treatment of advanced melanoma is still disappointing. In a multicenter randomized clinical trial to compare a chemotherapy (CT) with or without low doses of IL-2 and IFN (Bio-CT), the participating centers chose whether or not to add a nitrosourea, carmustine (BCNU) to the therapy. The aim of the present paper is to report the clinical results of the patients (pts) treated in both arms with BCNU. One hundred and seventy-six pts with advanced melanoma were enrolled in the study from 27 centers and a total of 18 pts also received BCNU in 3 centers. No further changes to the protocol criteria were allowed. One patient refused the treatment. No complete responses were observed. Irrespectively of the treatment arm, 9/17 pts showed a partial response to therapy (53%) (5/9 in the CT and 4/8 in the BioCT arm). The most important adverse events observed were hematological: 12 pts presented grade 3 (6 pts) or grade 4 (6 pts) leukocytopenia and 9 pts had grade 4 thrombocytopenia, all of which resolved spontaneously. The addition of a nitrosourea to CT or Bio-CT appears to improve response rates compared to the same regimens without nitrosourea. Patient tolerability is acceptable. Further studies using this combination are warranted.
Collapse
Affiliation(s)
- R Ridolfi
- Oncologia Medica, Ospedale Pierantoni, Forli, Italy.
| | | | | | | | | | | | | | | |
Collapse
|